LIGAND PHARMACEUTICALS (LGND) Stock Fundamental Analysis
NASDAQ:LGND - US53220K5048 - Common Stock
161.71 USD
+1.75 (+1.09%)
161.71 USD
0 (0%)
Taking everything into account, LGND scores 5 out of 10 in our fundamental rating. LGND was compared to 194 industry peers in the Pharmaceuticals industry. LGND has an excellent financial health rating, but there are some minor concerns on its profitability. LGND is growing strongly while it is still valued neutral. This is a good combination!
1. Profitability
1.1 Basic Checks
LGND had positive earnings in the past year.
In the past year LGND had a positive cash flow from operations.
In multiple years LGND reported negative net income over the last 5 years.
In the past 5 years LGND always reported a positive cash flow from operatings.
1.2 Ratios
LGND has a better Return On Assets (-8.00%) than 69.43% of its industry peers.
LGND's Return On Equity of -9.16% is fine compared to the rest of the industry. LGND outperforms 75.13% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8% | ||
| ROE | -9.16% | ||
| ROIC | N/A |
ROA(3y)0.61%
ROA(5y)1.2%
ROE(3y)0.46%
ROE(5y)1.58%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
LGND's Operating Margin has declined in the last couple of years.
With an excellent Gross Margin value of 93.05%, LGND belongs to the best of the industry, outperforming 95.85% of the companies in the same industry.
LGND's Gross Margin has been stable in the last couple of years.
LGND does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 93.05% |
OM growth 3Y-21.5%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.37%
GM growth 5Y0.62%
2. Health
2.1 Basic Checks
LGND does not have a ROIC to compare to the WACC, probably because it is not profitable.
LGND has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, LGND has more shares outstanding
Compared to 1 year ago, LGND has a worse debt to assets ratio.
2.2 Solvency
LGND has an Altman-Z score of 17.03. This indicates that LGND is financially healthy and has little risk of bankruptcy at the moment.
LGND has a Altman-Z score of 17.03. This is amongst the best in the industry. LGND outperforms 92.23% of its industry peers.
There is no outstanding debt for LGND. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 17.03 |
ROIC/WACCN/A
WACC9.97%
2.3 Liquidity
A Current Ratio of 5.45 indicates that LGND has no problem at all paying its short term obligations.
With a decent Current ratio value of 5.45, LGND is doing good in the industry, outperforming 73.58% of the companies in the same industry.
LGND has a Quick Ratio of 5.21. This indicates that LGND is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 5.21, LGND is doing good in the industry, outperforming 73.06% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.45 | ||
| Quick Ratio | 5.21 |
3. Growth
3.1 Past
LGND shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.80%, which is quite impressive.
LGND shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 13.44% yearly.
LGND shows a strong growth in Revenue. In the last year, the Revenue has grown by 40.53%.
LGND shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.80% yearly.
EPS 1Y (TTM)20.8%
EPS 3Y-3.83%
EPS 5Y13.44%
EPS Q2Q%14.29%
Revenue 1Y (TTM)40.53%
Revenue growth 3Y-15.51%
Revenue growth 5Y6.8%
Sales Q2Q%14.68%
3.2 Future
LGND is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.82% yearly.
LGND is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 20.10% yearly.
EPS Next Y22.58%
EPS Next 2Y15.32%
EPS Next 3Y14.82%
EPS Next 5Y13.82%
Revenue Next Year29.78%
Revenue Next 2Y22.11%
Revenue Next 3Y20.57%
Revenue Next 5Y20.1%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 26.77, which means the current valuation is very expensive for LGND.
Based on the Price/Earnings ratio, LGND is valued a bit cheaper than the industry average as 79.79% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 27.08. LGND is around the same levels.
Based on the Price/Forward Earnings ratio of 21.29, the valuation of LGND can be described as rather expensive.
Based on the Price/Forward Earnings ratio, LGND is valued a bit cheaper than the industry average as 74.61% of the companies are valued more expensively.
LGND is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 22.72, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.77 | ||
| Fwd PE | 21.29 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, LGND is valued a bit cheaper than the industry average as 76.17% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, LGND is valued a bit cheaper than the industry average as 77.20% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 62.34 | ||
| EV/EBITDA | 135.77 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
LGND's earnings are expected to grow with 14.82% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.19
PEG (5Y)1.99
EPS Next 2Y15.32%
EPS Next 3Y14.82%
5. Dividend
5.1 Amount
No dividends for LGND!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
161.71
+1.75 (+1.09%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners99.76%
Inst Owner Change1.65%
Ins Owners1.71%
Ins Owner Change3.79%
Market Cap3.17B
Analysts84.62
Price Target170.6 (5.5%)
Short Float %4.86%
Short Ratio4
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.98%
Min EPS beat(2)7.61%
Max EPS beat(2)10.36%
EPS beat(4)4
Avg EPS beat(4)14.14%
Min EPS beat(4)4.63%
Max EPS beat(4)33.98%
EPS beat(8)8
Avg EPS beat(8)38.28%
EPS beat(12)12
Avg EPS beat(12)65.25%
EPS beat(16)15
Avg EPS beat(16)61.42%
Revenue beat(2)2
Avg Revenue beat(2)10.64%
Min Revenue beat(2)6.44%
Max Revenue beat(2)14.84%
Revenue beat(4)4
Avg Revenue beat(4)13.45%
Min Revenue beat(4)6.44%
Max Revenue beat(4)24.96%
Revenue beat(8)8
Avg Revenue beat(8)14.01%
Revenue beat(12)11
Avg Revenue beat(12)13.22%
Revenue beat(16)14
Avg Revenue beat(16)14.34%
PT rev (1m)16.25%
PT rev (3m)16.55%
EPS NQ rev (1m)19.39%
EPS NQ rev (3m)22.58%
EPS NY rev (1m)12.06%
EPS NY rev (3m)12.37%
Revenue NQ rev (1m)18.31%
Revenue NQ rev (3m)26.95%
Revenue NY rev (1m)9.25%
Revenue NY rev (3m)9.92%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.77 | ||
| Fwd PE | 21.29 | ||
| P/S | 16.9 | ||
| P/FCF | 62.34 | ||
| P/OCF | 60.28 | ||
| P/B | 3.83 | ||
| P/tB | 11.19 | ||
| EV/EBITDA | 135.77 |
EPS(TTM)6.04
EY3.74%
EPS(NY)7.59
Fwd EY4.7%
FCF(TTM)2.59
FCFY1.6%
OCF(TTM)2.68
OCFY1.66%
SpS9.57
BVpS42.27
TBVpS14.45
PEG (NY)1.19
PEG (5Y)1.99
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8% | ||
| ROE | -9.16% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 93.05% | ||
| FCFM | 27.11% |
ROA(3y)0.61%
ROA(5y)1.2%
ROE(3y)0.46%
ROE(5y)1.58%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)1.42%
ROCE(5y)2.25%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-21.5%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.37%
GM growth 5Y0.62%
F-Score5
Asset Turnover0.2
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 5.04% | ||
| Cap/Sales | 0.93% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 259.88% | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.45 | ||
| Quick Ratio | 5.21 | ||
| Altman-Z | 17.03 |
F-Score5
WACC9.97%
ROIC/WACCN/A
Cap/Depr(3y)71.95%
Cap/Depr(5y)50.12%
Cap/Sales(3y)19.71%
Cap/Sales(5y)12.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.8%
EPS 3Y-3.83%
EPS 5Y13.44%
EPS Q2Q%14.29%
EPS Next Y22.58%
EPS Next 2Y15.32%
EPS Next 3Y14.82%
EPS Next 5Y13.82%
Revenue 1Y (TTM)40.53%
Revenue growth 3Y-15.51%
Revenue growth 5Y6.8%
Sales Q2Q%14.68%
Revenue Next Year29.78%
Revenue Next 2Y22.11%
Revenue Next 3Y20.57%
Revenue Next 5Y20.1%
EBIT growth 1Y-288.32%
EBIT growth 3Y-33.67%
EBIT growth 5YN/A
EBIT Next Year483.19%
EBIT Next 3Y133.64%
EBIT Next 5Y79.19%
FCF growth 1Y-48.59%
FCF growth 3Y10.8%
FCF growth 5YN/A
OCF growth 1Y-51.27%
OCF growth 3Y7.19%
OCF growth 5YN/A